Review Topical Sections

Possible pathophysiological roles of transglutaminase-catalyzed reactions in the pathogenesis of human neurodegenerative diseases

  • Transglutaminases (TG, E.C. 2.3.2.13) are related and ubiquitous enzymes that catalyze the cross linking of a glutaminyl residue of a protein/peptide substrate to a lysyl residue of a protein/peptide co-substrate. These enzymes are also capable of catalyzing other post-translational reactions important for cell life. The distribution and the physiological roles of human TGs have been widely studied in numerous cell types and tissues and recently their roles in several diseases have begun to be identified. It has been hypothesized that transglutaminase activity is directly involved in the pathogenetic mechanisms responsible for several human diseases. In particular, tissue TG (tTG, TG2), a member of the TG enzyme family, has been recently shown to be involved in the molecular mechanisms responsible for a very widespread human pathology, Celiac Disease (CD), one of the most common food intolerances described in the western population. The main food agent that provokes the strong and diffuse clinical symptoms has been known for several years to be gliadin, a protein present in a very large number of human foods derived from vegetables. Recently, some biochemical and immunological aspects of this very common disease have been clarified, and “tissue” transglutaminase, a multifunctional and ubiquitous enzyme, has been identified as one of the major factors. The aim of this review is to summarize the most recent findings concerning the relationships between the biochemical properties of the transglutaminase activity and the basic molecular mechanisms responsible for some human diseases, with particular reference to neuropsychiatric disorders. Possible molecular links between CD and neuropsychiatric disorders, and the use of transglutaminase inhibitors are also discussed.

    Citation: Enrica Serretiello, Martina Iannaccone, Federica Titta, Nicola G. Gatta, Vittorio Gentile. Possible pathophysiological roles of transglutaminase-catalyzed reactions in the pathogenesis of human neurodegenerative diseases[J]. AIMS Biophysics, 2015, 2(4): 441-457. doi: 10.3934/biophy.2015.4.441

    Related Papers:

    [1] Kai Xiao . Risk-seeking insider trading with partial observation in continuous time. AIMS Mathematics, 2023, 8(11): 28143-28152. doi: 10.3934/math.20231440
    [2] Jixiu Qiu, Yonghui Zhou . Insider trading with dynamic asset under market makers' partial observations. AIMS Mathematics, 2023, 8(10): 25017-25036. doi: 10.3934/math.20231277
    [3] Zongqi Sun, Peng Yang, Jing Wu, Yunpeng Fan . The defined contribution pension plan after retirement under the criterion of a revised loss considering the economic situation. AIMS Mathematics, 2024, 9(2): 4749-4761. doi: 10.3934/math.2024229
    [4] Ling Chen, Xiang Hu, Mi Chen . Optimal investment and reinsurance for the insurer and reinsurer with the joint exponential utility under the CEV model. AIMS Mathematics, 2023, 8(7): 15383-15410. doi: 10.3934/math.2023786
    [5] Zongqi Sun, Peng Yang, Ying Wang, Jing Lu . Research on the wealth management fees of defined contribution pensions during the pre-retirement stage. AIMS Mathematics, 2024, 9(12): 36102-36115. doi: 10.3934/math.20241713
    [6] Peng Yang . Robust optimal reinsurance-investment problem for $ n $ competitive and cooperative insurers under ambiguity aversion. AIMS Mathematics, 2023, 8(10): 25131-25163. doi: 10.3934/math.20231283
    [7] Wuyuan Jiang, Zechao Miao, Jun Liu . Optimal investment and reinsurance for the insurer and reinsurer with the joint exponential utility. AIMS Mathematics, 2024, 9(12): 35181-35217. doi: 10.3934/math.20241672
    [8] Jiuchao Ban, Yiran Wang, Bingjie Liu, Hongjun Li . Optimization of venture portfolio based on LSTM and dynamic programming. AIMS Mathematics, 2023, 8(3): 5462-5483. doi: 10.3934/math.2023275
    [9] Dennis Llemit, Jose Maria Escaner IV . Value functions in a regime switching jump diffusion with delay market model. AIMS Mathematics, 2021, 6(10): 11595-11609. doi: 10.3934/math.2021673
    [10] Hui Sun, Zhongyang Sun, Ya Huang . Equilibrium investment and risk control for an insurer with non-Markovian regime-switching and no-shorting constraints. AIMS Mathematics, 2020, 5(6): 6996-7013. doi: 10.3934/math.2020449
  • Transglutaminases (TG, E.C. 2.3.2.13) are related and ubiquitous enzymes that catalyze the cross linking of a glutaminyl residue of a protein/peptide substrate to a lysyl residue of a protein/peptide co-substrate. These enzymes are also capable of catalyzing other post-translational reactions important for cell life. The distribution and the physiological roles of human TGs have been widely studied in numerous cell types and tissues and recently their roles in several diseases have begun to be identified. It has been hypothesized that transglutaminase activity is directly involved in the pathogenetic mechanisms responsible for several human diseases. In particular, tissue TG (tTG, TG2), a member of the TG enzyme family, has been recently shown to be involved in the molecular mechanisms responsible for a very widespread human pathology, Celiac Disease (CD), one of the most common food intolerances described in the western population. The main food agent that provokes the strong and diffuse clinical symptoms has been known for several years to be gliadin, a protein present in a very large number of human foods derived from vegetables. Recently, some biochemical and immunological aspects of this very common disease have been clarified, and “tissue” transglutaminase, a multifunctional and ubiquitous enzyme, has been identified as one of the major factors. The aim of this review is to summarize the most recent findings concerning the relationships between the biochemical properties of the transglutaminase activity and the basic molecular mechanisms responsible for some human diseases, with particular reference to neuropsychiatric disorders. Possible molecular links between CD and neuropsychiatric disorders, and the use of transglutaminase inhibitors are also discussed.


    In 1985, Kyle [1] established an equilibrium model in which a neutral trader possesses private information on the value of a risky asset. Subsequently, Back [2] revisited a continuous-time version of the Kyle model. Using stochastic control theory, signal filtering techniques, and signal filtering theory, Back derived a unique equilibrium within a certain class.

    In real trading markets, market equilibrium is influenced by a variety of key factors. In 2020, Banerjee and Breon-Drish[3] extended Kyle's framework [1] by incorporating unobservable and costly information acquisition. They assumed that the volatility of liquidity traders follows a general, positive stochastic process, which directly implies that insider information evolves over time. Subsequently, Han et al. [4] examined the long-range dependence characteristic of market liquidity. More recently, Qiu and Zhou [5] not only modeled the volatility of risky assets as a random process, but also developed a random deadline insider trading model under dynamic asset conditions.

    From the above mentioned, we realize that the impact of dynamic assets on market equilibrium is significant, because insider will update his/her private information over time. Moreover, insider behavior is one of the key factors affecting market equilibrium. For example, Baruch [6] considered a risk-averse monopolist model and assumed that liquidity traders' instantaneous demand depended on the cost of trading. His conclusion indicated that market depth increased over time. Later, Cho [7] extended the uniqueness result from the model of Kyle [1] and Back [2], and pointed out that market liquidity decreases over time if an insider is risk-averse. Recently, Xiao and Zhou [8] also considered a risk-averse model, but, unlike Baruch [6] and Cho [7], they analyzed a risky asset whose value is driven by an arithmetic Brownian motion, as in [9,10], and established a closed-form equilibrium with a risk-averse insider. In fact, there is lots of literature on continuous-time risk-averse models [11,12], and discrete-time risk-averse models [13,14]. However, risk-seeking literature has been less relatively addressed.

    Why do most insider trading models tend to treat insiders as risk-averse or risk-neutral individuals? Tversky and Kahneman [15] provided their perspective in 1979, suggesting that when investors face uncertain decision-making, their investment behavior deviates from the rational models of classical financial theory due to the influence of personal and social factors. The risk attitude and behavior patterns often deviate from the optimal models of classical financial theory. They argued that when an investor is confronted with certain gains, they are generally risk-averse, seeking to minimize risk. However, when faced with certain losses, the investor is more inclined to take risks, focusing on the volatility of returns rather than the stability of those returns. As a result, risk-seeking investors are more likely to choose higher-risk assets in pursuit of higher returns.

    From the perspective of behavioral economics, it is reasonable for most insider trading models to assume that insiders are either risk-averse or risk-neutral. However, it is important to note that this assumption reflects a subjective tendency, not an absolute truth. In reality, it is entirely possible for an insider to be a risk-seeking investor, as psychological factors, such as an abnormal mentality, can significantly influence an investor's risk preferences. Research by Frank et al. [16] indicates that CEOs, for example, may exhibit lower self-control, abusing their informational advantages to make profits, sometimes engaging in more aggressive trading behaviors. Furthermore, overconfidence in investors often leads to excessive self-assurance in their judgments and an overestimation of their chances of success. This, in turn, can lead to overreaction and excessive trading, causing the investor to behave as a risk-seeking agent. Zhou[17] examined a public disclosure model where an insider, overconfident in his private information, initially refrained from aggressive trading. This strategy aimed to preserve information for future trades, reflecting the insider's risk-seeking behavior. Kyle et al.[18] studied a continuous-time model and described the overconfident trading behavior of oligopolistic insider with exponential utility. In addition, several studies [19,20] have explored these behaviors, demonstrating that insiders, under certain conditions, can indeed act as risk-seeking investors.

    Kyle et al.[18] describe a symmetric continuous-time model of trading among relatively overconfident, oligopolistic informed traders with exponential utility. Traders agree to disagree about the precisions of their continuous flows of Gaussian private information.

    In fact, in 2010, Gong and Zhou [21] examined mixed equilibrium in a rationally expected price model under different risk preferences, noting that market liquidity increases over time. Subsequently, Gong and Zhou [22] developed a risk-seeking insider trading model within the context of Stackelberg equilibria. In 2023, Xiao [23] investigated a risk-seeking insider trading model in a continuous-time framework, where market makers could observe partial information about the risky asset. Using filtering theory and the dynamic programming principle, he proved the uniqueness and existence of a solution to the model. Unfortunately, in his assumptions, the risky asset is static, so market makers' partial information is integrated into the initial price at the beginning, making the partial observation coefficient always zero. In fact, partial observation has been studied by many researchers [24,25,26], but their models typically assume the risky asset is static. In my view, the risky asset should be dynamic. Therefore, we aim to improve and extend the previous model.

    Next, this paper makes the following assumptions: (i) the insider is risk-seeking, (ii) the risky asset is dynamic, and (iii) market makers can receive partial signals about the risky asset. The remainder of the paper is organized as follows. Section 2 presents the preliminaries, including a definition of risk-seeking linear equilibrium. Section 4 outlines some necessary conditions for market efficiency. The main conclusions, including the existence and uniqueness of the equilibrium, are presented in Section 5. Section 6 provides numerical simulations of the equilibrium, and conclusions are drawn in Section 7.

    Before introducing our model, we first assume that all randomness originates from a common filtered probability space $ (\Omega, {\cal F}, \{{\cal F}_t\}_{t\geq0}, P) $, which satisfies the usual conditions[27]. Following this, we present the formulation of the optimal filtering problem below:

    $ dθt=[a0(t,ξ)+a1(t,ξ)θt]dt+Σ2i=1bi(t,ξ)dWi(t),
    $
    (2.1)
    $ dξt=[A0(t,ξ)+A1(t,ξ)θt]dt+Σ2i=1Bi(t,ξ)dWi(t),
    $
    (2.2)

    Theorem 2.1. [28] Let $ (\theta, \xi) $ be a random process with differentials given by (2.1) and (2.2), and the conditions (1)–(10) be satisfied in [28]$ \{$12.3 Optimal Filtering Equations in Several Dimensions$ \}$. Then the vector $ m_t = M(\theta_t|\mathbf{F}_t^\xi) $ and the matrix $ \gamma_t = M((\theta_t-m_t)(\theta_t-m_t)^*|\mathbf{F}_t^\xi) $ are unique continuous $ \mathbf{F}_t^\xi $-measurable for any t solutions of the system of equations

    $ dmt=[a0(t,ξ)+a1(t,ξ)mt]dt+[(bB)(t,ξ)+γtA1(t,ξ)](BB)1(t,ξ)[dξt(A0(t,ξ)+A1(t,ξ)mt)dt],
    $
    (2.3)
    $ dγt=(a1(t,ξ)γt+γta1((t,ξ))+(bb)(t,ξ)[(bB)(t,ξ)+γtA1(t,ξ)](BB)1(t,ξ)[(bB)(t,ξ)+γtA1(t,ξ)])dt
    $
    (2.4)

    where $ B\circ B = B_1\circ B_1^*+B_2\circ B_2^* $, $ b\circ B = b_1\circ B_1^*+b_2\circ B_2^* $, $ b\circ b = b_1\circ b_1^*+b_2\circ b_2^* $, and $ C^* $ is a transpose of $ C $.

    In a risky market, there is a risky asset traded in a finite continuous-time interval [0, 1], with its value, denoted as $ {v_t} $, evolving according to

    $ vt=v0+t0σvdBvs,
    $
    (3.1)

    where $ v_0 $ is normally distributed with mean 0 and variance $ \sigma_{v0}^2 $, and $ B_{v} $ is a standard Brownian motion. There are three types of traders participating in the market:

    (ⅰ) risk-seeking insider, who possesses the information regarding the liquidation value $ v_t $, and chooses his/her trading strategy $ x_{t} $ as follows:

    $ dxt=βt(vtpt)dt,x0=0,
    $
    (3.2)

    where $ \beta $ is a positive deterministic function, referred to as insider trading intensity[1];

    (ⅱ) liquidity traders, who submit random trading volume $ z_t $ in the following form[7]:

    $ zt=σzBzt,z0=0,
    $
    (3.3)

    where $ \sigma_z $ is a positive deterministic constant, and $ B_{z} $ is a standard Brownian motion that is independent of $ v_t $;

    (ⅲ) risk-neutral market makers, who observe the total orders of risk-seeking insider and noise traders (but do not observe them separately)

    $ yt=xt+zt
    $
    (3.4)

    and obtain a signal $ u_t $ on risky asset $ v_t $

    $ ut=vt+ϵt
    $
    (3.5)

    where $ \epsilon_t = \epsilon_0+\int_0^t\sigma_{\epsilon}dB{\epsilon s} $ is independent of $ v_t $ and $ B_{zt} $, and $ \epsilon_0\sim N(0, \sigma_{\epsilon 0}^{2}) $. Subsequently, based on the trading volume $ y_t $ and the signal $ u_t $, they set the market price $ p_t $ as a linear function satisfying:

    $ dpt=λytdyt+λutdut,  p0=0,
    $
    (3.6)

    where $ \lambda_y $ and $ \lambda_u $ are two deterministic, measurable, and differentiable functions, referred to as the market liquidity parameter and the partial observation coefficient, respectively.

    Then, approximately, the ex-ante profit for insider from time $ t $ to 1 is given by:

    $ πt=1tβs(vsps)2ds.
    $
    (3.7)

    Based on the characteristics of risk-seeking insider, we assume she/he has an exponential utility function from time $ t $ to 1 in the following form:

    $ U(πt)=expπt.
    $
    (3.8)

    Of course, the following conditions should be guaranteed, $ \int_0^1\lambda_t^2dt < \infty $, $ \int_0^1\beta_t^2dt < \infty $, and $ E (\exp^{\int_t^1\beta_s(v_s-p_s)^2ds}) < \infty $. Otherwise, it is difficult to guarantee its well-posedness. Next, the concept of equilibrium will be given as follows.

    Definition 3.1. A risk-seeking linear equilibrium is a series $ (\beta, (\lambda_y, \lambda_u)) $ such that

    ($ i $) maximization of utility: for the given $ (\lambda_y, \lambda_u) $, the trading intensity $ \beta $ maximizes

    $ E[U(πt)]=E[exp1tβs(vsps)2ds],
    $
    (3.9)

    where the insider's information domain $ {\cal F}^I_{t} = \sigma\{v\}\vee\sigma\{p_s, 0\leq s\leq t\} $ for $ t\in[0, 1) $, and

    ($ ii $) market semi-strong efficiency: for the given $ \beta $, a pair $ (\lambda_y, \lambda_u) $ ought to satisfy

    $ t0(λysdys+λusdus)=E[vt|FMt],
    $
    (3.10)

    where $ {\cal F}_t^{M} = \sigma\{u\}\bigvee \sigma\{y_s, 0\leq s \leq t\} $ for $ t\in[0, 1) $.

    Remark 3.1. In this model, market makers can't obtain profit from trading, that is to say

    $ E[(\tilde{v}-\tilde{p})\tilde{y}|\tilde{y},\tilde{q}] = \tilde{y}E[(\tilde{v}-\tilde{p})|\tilde{y},\tilde{q}] = \tilde{y}(\tilde{p}-\tilde{p}) = 0. $

    Therefore, if market makers are not risk-neutral, the pricing process is not a martingale process, which will eventually lead to unfair market.

    In our model, the signal-observation system is given by

    $ Signal  vt: dvt=σvdBvt,Obervation yt: dξt=(A0+A1vt)dt+A2dBvt+A3dBt,
    $
    (4.1)

    where $ \xi_{t} = (ytut)

    $, $ \xi_{0} = (0v0+ϵ0)
    $, $ A_{0} = (ptβt0)
    $, $ A_{1} = (βt0)
    $, $ A_{2} = (0σv)
    $, $ A_{3} = (σz00σϵ)
    $, $ B_t = (BztBϵt)
    $.

    By Theorem 2.1, we get

    $ dpt=dE[vt|FMt]=Σtβtσ2zdyt+σ2vσ2v+σ2ϵdut,
    $
    (4.2)

    where

    $ λyt=Σtβtσ2z,λut=σ2vσ2v+σ2ϵ
    $
    (4.3)

    and

    $ dΣtdt=Σ0Σ2tβ2tσ2z,
    $
    (4.4)

    in addition, $ \Sigma_{t} = E[(v_t-p_t)^{2}] $ is called residual information [1] with $ \Sigma_0 = \frac{\sigma_{\epsilon 0}^{2}\sigma_{v0}^{2}}{\sigma_{v0}^{2}+\sigma_{\epsilon 0}^{2}} $.

    In the following section, we will investigate the risk-seeking linear equilibrium. Let $ {{m}}_s = v_s-p_s $, combine (3.1) with (3.6), then

    $ dmt=λytβtmtdt+(σv(1λut),λytσz,λutσϵ)(dBvtdBztdBϵt)
    $
    (5.1)

    Let $ (\beta, (\lambda_y, \lambda_u)) $ be a linear equilibrium. From Definition 3.1, the insider's value function for $ t\in[0, 1] $ is given by

    $ V(t,mt)=max˜βU(t,β)E[exp1t˜βsms2ds|FIt]=E[exp1tβsm2sds|FIt],
    $
    (5.2)

    where $ {\cal U}(t, \beta) $ is the collection of the functions $ \tilde{\beta} $, such that $ \tilde{\beta}_s = \beta_s $ for $ 0\leq s\leq t $, and the two conditions for (5.2) are ensured

    $ limt1V(t,mt)=1,  Σ0=σ2z210λ2ytdt.
    $
    (5.3)

    It is obvious that the first result is immediate, and the second can be deduced from Eqs (4.2) and (4.4), along with the equality $ \lim_{t\to 1^{-}}\Sigma_{t} = 0 $.

    In fact, it is straightforward to apply Bellman's principle to the stochastic version of the insider trading problem.

    Proposition 5.1. Given $ t\in [0, 1) $, for $ \hat{t}\in [t, 1] $,

    $ V(t,mt)=max˜βU(t,β)E[exp1t˜βsms2ds(1expˆtt˜βsms2ds)+V(ˆt,mˆt)|FIt].
    $
    (5.4)

    Proof. Omit.

    With the help of dynamic programming principle[27], we derive the following Hamilton-Jacobi-Bellman (HJB) equation.

    Proposition 5.2. If the insider's value function is $ V(t, m_{t}) $ in Proposition 5.1, then the $ HJB $ equation is

    $ supβR[Vt+12Vmm(σ2v(1λut)2+λ2ytσ2z+λ2utσ2ϵ)+β(λtmt(mtVλytVm)]=0.
    $
    (5.5)

    Proof. By Proposition 5.1 with $ \hat{t}-t\rightarrow o $ and $ It\hat{o}s $ formula, we obtain

    $ \frac{V(\hat{t},m_{\hat{t}})- V(t,m_{t})}{\hat{t}-t}+\frac{\exp^{\int_{t}^{1}\tilde{\beta}_{s}{{m_{s}}}^{2}d{s}}(1-\exp^{-\int_{t}^{\hat{t}}\tilde{\beta}_{s}{{m_{s}}}^{2}d{s}})}{\hat{t}-t} = 0, $

    obviously,

    $ dV(t,m_{t}) = V_tdt-\lambda_{yt}\beta_tm_tV_mdm+V_m((\sigma_v(1-\lambda_{ut}),-\lambda_{yt}\sigma_z,\lambda_{ut}\sigma_{\epsilon}) (dBvtdBztdBϵt)
    ) $
    $ +\frac{1}{2}V_{mm}(\sigma_v^2(1-\lambda_{ut})^2+\lambda_{yt}^2\sigma_z^2+\lambda_{ut}^2\sigma_{\epsilon}^2)dt $

    or

    $ E(dV(t,m_{t})) = V_tdt+\lambda_{yt}\beta_tm_tV_mdt+\frac{1}{2}V_{mm}(\sigma_v^2(1-\lambda_{ut})^2+\lambda_{yt}^2\sigma_z^2+\lambda_{ut}^2\sigma_{\epsilon}^2)dt, $

    and $ \frac{1-\exp^{-\int_{t}^{\hat{t}}{\beta}_{s}{{m_{s}}}^{2}d{s}}}{\hat{t}-t}\thicksim \beta_t{{m_{t}}}^{2} $ as $ \hat{t} \rightarrow t $. Hence, we have

    $ supβR[Vt+12Vmm(σ2v(1λut)2+λ2ytσ2z+λ2utσ2ϵ)+βmt(mtVλytVm)]=0.
    $
    (5.6)

    Proposition 5.3. If the insider's value function satisfies (5.5), then it can be portrayed as

    $ V(t,m_{t}) = g_0(tan(c_1-\sigma_z^2\tau t)cot c_1)^{1/2}\exp^{\frac{m_{t}^{2}}{2\lambda_{yt}}}, $

    where

    $ λyt=τtan(c1σ2zτt),
    $
    (5.7)
    $ g0=(tan(c1σ2zτ)cotc1)1/2,
    $
    (5.8)
    $ τ=(σ2vσ2z(1λut)2+σ2ϵσ2zλ2ut)1/2,
    $
    (5.9)

    and the constant $ c_1 $ satisfies the following equation,

    $ \cot (c_{1}-\sigma_z^2\tau)-\cot c_{1} = \frac{2\Sigma_0}{\tau}+\sigma_z^2\tau. $

    Proof. We know that the $ HJB $ equation (5.5) is equivalent to the following system:

    $ V_t+\frac{1}{2}V_{mm}(\sigma_v^2(1-\lambda_{ut})^2+\lambda_{yt}^2\sigma_z^2+\lambda_{ut}^2\sigma_{\epsilon}^2) = 0, $
    $ βmt(mtVλytVm)=0.
    $
    (5.10)

    In the system (5.10), the second equation can be viewed as an ordinary differential equation in terms of $ m_t $, which leads to the following:

    $ V(t,mt)=g(t)expm2t2λyt,
    $
    (5.11)

    where $ g(t) $ is a deterministic function on [0, 1].

    Substituting (5.11) into the first equation in system (5.10), we obtain

    $ \frac{dg(t)}{dt}+g(t)\frac{m_{t}^{2}}{2}\frac{d(\frac{1}{\lambda_{yt}})}{dt}+\frac{g(t)}{2}(\frac{m_t^2}{\lambda_{yt}^2}+\frac{1}{\lambda_{yt}})(\sigma_v^2(1-\lambda_{ut})^2+\lambda_{yt}^2\sigma_z^2+\lambda_{ut}^2\sigma_{\epsilon}^2) = 0, $

    and it is equivalent to the following two equations

    $ dg(t)dt+g(t)21λyt(σ2v(1λut)2+λ2ytσ2z+λ2utσ2ϵ)=0,
    $
    (5.12)
    $ g(t)m2t2d(1λyt)dt+g(t)m2t21λ2yt(σ2v(1λut)2+λ2ytσ2z+λ2utσ2ϵ)=0.
    $
    (5.13)

    From the Eq (5.13), we get

    $ \frac{d(\frac{1}{\lambda_{yt}})}{dt} = -\sigma_{z}^{2}-(\sigma_v^2(1-\lambda_{ut})^2+\lambda_{ut}^2\sigma_{\epsilon}^2)(\frac{1}{\lambda_{yt}})^2. $

    Let $ \tau = (\frac{\sigma_v^2}{\sigma_z^2}(1-\lambda_{ut})^2+\frac{\sigma_{\epsilon}^2}{\sigma_z^2}\lambda_{ut}^2)^{1/2}, $ then we have

    $ λyt=τtan(c1σ2zτt)
    $
    (5.14)

    where $ c_1 = arctan(\frac{\tau}{\lambda_{y0}}) $. We take it into the Eq (5.12), then

    $ gt=g0expσ2z2t0tan(c1σ2zτs)τ(τ2+τ2tan2(c1σ2zτs))ds=g0(tan(c1σ2zτt)cotc1)1/2,
    $
    (5.15)

    where $ g_{0} = \exp^{\frac{\sigma_z^2}{2}\int_0^1\frac{tan(c_1-\sigma_z^2\tau s)}{\tau}(\tau+\frac{\tau^{2}}{tan^2(c_1-\sigma_z^2\tau s)})ds} = (tan(c_1-\sigma_z^2\tau)cot c_1)^{1/2} $. According to the boundary conditions in (5.3), the constant $ c_{1} $ can be solved by

    $ cot(c1σ2zτ)cotc1=2Σ0τ+σ2zτ.
    $
    (5.16)

    Theorem 5.1. Let $ -\frac{\pi}{2} < c_1-\tau\sigma_{z}^{2}t < \frac{\pi}{2} $, then there is a unique linear equilibrium $ (\beta, \lambda) $ satisfying

    $ \beta_{t} = \frac{\sigma_{z}^{2}\tau\cot(c_1-\tau\sigma_z^2t)}{(\Sigma_0+\tau^2\sigma_z^2)(t-1)+\tau(cot(c_1-\tau\sigma_z^2)-cot(c_1-\tau\sigma_z^2t)). }, $
    $ \lambda_{yt} = \frac{\tau}{tan(c_1-\sigma_z^2\tau t)}, \lambda_{ut} = \frac{\sigma_{v}^{2}}{\sigma_{v}^{2}+\sigma_{\epsilon}^{2}}. $

    At the equilibrium, the residual information $ \Sigma_{t} $ is

    $ \Sigma_{t} = (\Sigma_0+\tau^2\sigma_z^2)(t-1)+\tau(cot(c_1-\tau\sigma_z^2)-cot(c_1-\tau\sigma_z^2t)). $

    and the insider's total ex-ante utility

    $ E[V(0,m_0)] = \sqrt{\frac{\lambda_{y0}}{\lambda_{y0}-\Sigma_{0}}}(tan(c_1-\sigma_z^2\tau)cot c_1)^{1/2}, $

    where $ c_1 $ is satisfied with the following equation:

    $ \cot (c_{1}-\sigma_z^2\tau)-\cot c_{1} = \frac{2\Sigma_0}{\tau}+\sigma_z^2\tau $

    Proof. From the Eq (4.4), we have

    $ dΣtdt=Σ0σ2zλ2yt,
    $
    (5.17)

    Taking (5.14) into it, we have

    $ \Sigma_{t} = (\Sigma_0+\tau^2\sigma_z^2)(t-1)+\tau(cot(c_1-\tau\sigma_z^2)-cot(c_1-\tau\sigma_z^2t)). $

    Again, together with $ \lambda_{yt} = \frac{\Sigma_{t}\beta_{t}}{\sigma_{z}^{2}} $ in (4.3), we obtain

    $ \beta_{t} = \frac{\sigma_{z}^{2}\tau\cot(c_1-\tau\sigma_z^2t)}{(\Sigma_0+\tau^2\sigma_z^2)(t-1)+\tau(cot(c_1-\tau\sigma_z^2)-cot(c_1-\tau\sigma_z^2t)). }. $

    By the properties of expectation, we have

    $ E[V(0,m_0)] = \sqrt{\frac{\lambda_{y0}}{\lambda_{y0}-\Sigma_{0}}}(tan(c_1-\sigma_z^2\tau)cot c_1)^{1/2}, $

    where

    $ \cot (c_{1}-\sigma_z^2\tau)-\cot c_{1} = \frac{2\Sigma_0}{\tau}+\sigma_z^2\tau. $

    The proof is complete.

    Corollary 5.1. In Theorem 5.1, the following result holds:

    As time progresses, both market liquidity and optimal trading intensity increase simultaneously; the partial observation coefficient remains constant, whereas residual information decreases.

    Proof. Omit.

    In Theorem 5.1 and Corollary 5.1, we provide some theoretical characteristics of equilibrium. Next, we will present numerical simulations for the equilibrium. In order to understand the equilibrium characteristics of dynamic assets, we will compare them with the equilibrium of static assets [23]. In Xiao's article[23], a unique linear equilibrium $ (\beta, \lambda) $ is presented, satisfying

    $ \beta_{t} = \frac{c_{1}-\sigma_{z}^{2}}{1-t},\; \lambda_{yt} = \frac{1}{c_{1}-\sigma_{z}^{2}t},\; \lambda_{ut} = 0, $
    $ \Sigma_{t} = \frac{1}{c_{1}-\sigma_{z}^{2}}-\frac{1}{c_{1}-\sigma_{z}^{2}t}. $

    where

    $ \Sigma_0 = \frac{\sigma_{\epsilon 0}^{2}\sigma_{v0}^{2}}{\sigma_{v0}^{2}+\sigma_{\epsilon 0}^{2}}, c_{1} = \frac{\sigma_{z}^{2}+\sqrt{\sigma_{z}^{4}+\frac{4\sigma_{z}^{2}}{\Sigma_{0}}}}{2}. $

    In the following, we will examine the various characteristics of market equilibrium individually. To simplify the calculations, we assume that $ \sigma_{v}^{2} = \sigma_{v0}^{2}, \sigma_{\epsilon 0}^{2} = \sigma_{\epsilon}^{2} $. For more intuitive, Table 1 provides some special parameters. We mainly compared Xiao's model[23], which is a static risky asset.

    Table 1.  Partial special parameters in market equilibrium.
    Author (Volatility parameters) Market characteristic parameters
    $ \Sigma_0 $ $ c_1 $ $ \lambda_{ut} $
    Our($ \sigma_{v}^{2}=\sigma_{v0}^{2}=0.4, \sigma_{\epsilon 0}^{2}=\sigma_{\epsilon}^{2}=0.2 $) 0.1333 0.679 0.1333
    Xiao($ \sigma_{v}^{2}=\sigma_{v0}^{2}=0.4, \sigma_{\epsilon 0}^{2}=\sigma_{\epsilon}^{2}=0.2 $) 0.1333 1.3299 0
    Our($ \sigma_{v}^{2}=\sigma_{v0}^{2}=1, \sigma_{\epsilon 0}^{2}=\sigma_{\epsilon}^{2}=0.5 $) 0.3333 0.8526 0.6667
    Xiao($ \sigma_{v}^{2}=\sigma_{v0}^{2}=1, \sigma_{\epsilon 0}^{2}=\sigma_{\epsilon}^{2}=0.5 $) 0.3333 1.5 0
    Our($ \sigma_{v}^{2}=\sigma_{v0}^{2}=4, \sigma_{\epsilon 0}^{2}=\sigma_{\epsilon}^{2}=1 $) 0.8 1.2083 0.8
    Xiao($ \sigma_{v}^{2}=\sigma_{v0}^{2}=4, \sigma_{\epsilon 0}^{2}=\sigma_{\epsilon}^{2}=1 $) 0.8 1.7248 0
    Our($ \sigma_{v}^{2}=\sigma_{v0}^{2}=6, \sigma_{\epsilon 0}^{2}=\sigma_{\epsilon}^{2}=1 $) 0.8571 1.234 0.8571
    Xiao($ \sigma_{v}^{2}=\sigma_{v0}^{2}=6, \sigma_{\epsilon 0}^{2}=\sigma_{\epsilon}^{2}=1 $) 0.8571 1.6902 0

     | Show Table
    DownLoad: CSV

    In Figure 1, we intuitively illustrate the characteristics of equilibrium and observe how market liquidity evolves over time. It is evident that market liquidity increases exponentially. When comparing dynamic and static risky asset, market liquidity in dynamic assets is higher than in static assets when the volatility of risky asset is low. However, as the volatility of risky asset increases, market liquidity in dynamic risky asset initially becomes lower than in static assets, but eventually surpasses that of static assets. This suggests that the volatility of dynamic risky asset is a key factor in determining the level of market liquidity and the activity of the risk market.

    Figure 1.  $ \lambda_y $ Varying with time t.

    In Figure 2, whether the risk assets are dynamic or static, the partial observation coefficient remains constant over time. Moreover, as the volatility of risk assets increases, the partial observation coefficient steadily increases. However, the partial observation coefficient always remains zero in the case of static assets. In fact, the partial observation information in static assets will be integrated into market pricing initially, hence the partial observation coefficient remains zero. Unlike static assets, dynamic risk assets are continuously changing, which leads to partial observation coefficients fluctuating with volatility.

    Figure 2.  Partial observation coefficient varying with time t.

    In Figure 3, it is evident that the insider's residual information consistently decreases when the risky asset remains static. Furthermore, when the volatility of the risky asset is low, the insider's residual information gradually decreases. However, as the volatility of the risky asset increases, at the beginning of trading, the insider's residual information not only fails to decrease but also increases, which contradicts our initial intuition. This phenomenon can be explained by the insider's characteristics and the fundamental significance of residual information. First, the insider is generally risk-seeking, and a risk-seeking insider is less likely to release private information early in the trading process. Moreover, considering the expression for residual information, $ \Sigma_t = E[(v_t-p_t)^2] $, where $ p_t = E[v_t|{\cal F}_t^M] $, we can see that an increase in residual information $ \Sigma_t $ must arise from one of two conditions: (1) the market maker's pricing deviates from the true price, or (2) the risky asset $ v_t $ experiences significant volatility. Hence, this explains why the release of private information is reduced initially and why residual information increases when volatility is high.

    Figure 3.  $ \Sigma $ Varying with time t.

    In Figure 4, when the volatility of risk assets is low, the trading intensity of dynamic risk assets is higher than that of static risk assets. However, as the volatility of risk assets increases, the trading intensity of dynamic risk assets gradually decreases, eventually falling below that of static risk assets. When volatility is low, the insider can more effectively control the information, resulting in relatively high trading intensity. In contrast, as volatility increases, the insider becomes more cautious, leading to a lower trading intensity. This suggests that the stability of information plays a crucial role in influencing the insider's trading behavior.

    Figure 4.  $ \beta $ Varying with time t.

    In this paper, we establish the existence and uniqueness of the linear equilibrium in a continuous-time insider trading model, where the insider is assumed to be risk-seeking, and market makers observe partial signals on the risky asset; moreover, the risky asset is assumed to be driven by Brownian motion.

    This paper has found the above conclusion: (ⅰ) the partial observation coefficient remains constant over time for both dynamic and static risk assets. It increases with volatility in dynamic assets but stays zero for static ones, as their partial observation information is quickly integrated into market pricing. In contrast, dynamic assets cause fluctuations in the coefficient.

    (ⅱ) In a risk-seeking trading market, dynamic risky assets play a key role in influencing market equilibrium. When the volatility of these assets is low, market liquidity remains relatively stable, with a steady, albeit slight, increase over time. However, as the volatility of risky assets increases, market liquidity undergoes exponential changes, significantly enhancing liquidity and fostering market development. This aligns with economic intuition: when volatility is high, the insider finds it more difficult to manage these assets, which in turn makes it harder for them to generate profits. In comparison to risk-averse and risk-neutral agents, liquidity traders reduced losses, and their participation becomes more pronounced in a risk-seeking environment. To maximize potential profits, insider is also more likely to engage actively in trading.

    (ⅲ) The insider's residual information decreases when the risky asset remains unchanged. Under low volatility, the residual information steadily declines. However, as the volatility increases, the residual information initially increases, which contradicts intuition. This can be attributed to the insider's risk-seeking behavior, as they are less inclined to disclose private information early in trading. The residual information will increase if market makers' pricing deviates from the true value or when asset volatility is high, explaining the delayed release of information and the corresponding increase in residual information with higher volatility.

    (ⅳ) When volatility is low, dynamic risk assets trading intensity is higher than that of in static assets. However, as volatility increases, the trading intensity of dynamic assets diminishes, eventually falling below that of static assets. In a low-volatility environment, insiders can more effectively manage information, leading to greater trading activity. In contrast, rising volatility prompts insiders to adopt a more cautious stance, reducing trading intensity. This highlights the crucial role of information stability in influencing insider trading behavior.

    On the whole, at equilibrium, as time goes by, both market liquidity and trading intensity increase rapidly in the later, while residual information decreases slowly at the beginning, and partial observation coefficient is only related to randomness but independent of time. Specifically, the market liquidity characteristic suggests that the insider is more willing to trade and has a stronger desire to trade when less residual information is available.

    Note that, our model extends Kyle's (1985) framework [1] by incorporating a risk-seeking perspective. In Kyle's original model, market liquidity is assumed to be constant. In contrast in risk aversion [6,7,12] models, the market liquidity typically decreases over time. Different from the models mentioned above, in our model, market liquidity is an increasing function with time. From a broader perspective, it is beneficial for market development when the insider adjusts their risk appetite appropriately.

    The author declares that he has not used Artificial Intelligence (AI) tools in the creation of this article.

    The author want to thank Professor Yonghui Zhou, who carefully revised our manuscript, and provided many suggestions and assistance on the review comments. The paper is supported by Guizhou QKZYD[2022]4055, the innovative exploration and new academic seedling project of Guizhou University of Finance and Economics (No. 2022XSXMB25).

    The author declares no conflict of interest in this paper.

    [1] Folk JE (1983) Mechanism and basis for specificity of transglutaminase-catalyzed e-(g-glutamyl)lysine bond formation. Adv Enzymol Relat Areas Mol Biol 54: 1-56.
    [2] Lorand L, Conrad S M (1984) Transglutaminases. Mol Cell Biochem 58: 9-35. doi: 10.1007/BF00240602
    [3] Piacentini M, Martinet N, Beninati S, et al. (1988) Free and protein conjugated-polyamines in mouse epidermal cells. Effect of high calcium and retinoic acid. J Biol Chem 263: 3790-3794.
    [4] Kim CY, Quarsten H, Bergseng E, et al. (2004) Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci U S A 101: 4175-4179. doi: 10.1073/pnas.0306885101
    [5] Fleckenstein B, Qiao SW, Larsen MR (2004) Molecular characterization of covalent complexes between tissue transglutaminase and gliadin peptides. J Biol Chem 279: 17607-17616. doi: 10.1074/jbc.M310198200
    [6] Song Y, Kirkpatrick LL, Schilling AB, et al. (2013) Transglutaminase and polyamination of tubulin: posttranslational modification for stabilizing axonal microtubules. Neuron 78: 109-123. doi: 10.1016/j.neuron.2013.01.036
    [7] Achyuthan KE, Greenberg CS (1987) Identification of a guanosine triphosphate-binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity. J Biol Chem 262: 1901-1906.
    [8] Hasegawa G, Suwa M, Ichikawa Y, et al. (2003) A novel function of tissue-type transglutaminase: protein disulfide isomerase. Biochem J 373: 793-803. doi: 10.1042/bj20021084
    [9] Lahav J, Karniel E, Bagoly Z, et al. (2009) Coagulation factor XIII serves as protein disulfide isomerase. Thromb Haemost 101: 840-844.
    [10] Smethurst PA, Griffin M (1996) Measurement of tissue transglutaminase activity in a permeabilized cell system: its regulation by calcium and nucleotides. Biochem J 313: 803-808. doi: 10.1042/bj3130803
    [11] Nakaoka H, Perez DM, Baek KJ, et al. (1994) Gh: a GTP-binding protein with transglutaminase activity and receptor signalling function. Science 264: 1593-1596. doi: 10.1126/science.7911253
    [12] Gentile V, Porta R, Chiosi E, et al. (1997) Tissue transglutaminase and adenylate cyclase interactions in Balb-C 3T3 fibroblast membranes. Biochim Biophys Acta 1357: 115-122. doi: 10.1016/S0167-4889(97)00024-4
    [13] Nanda N, Iismaa SE, Owens WA, et al. (2001)Targeted inactivation of Gh/tissue transglutaminase II. J Biol Chem 276: 20673-20678.
    [14] Mian S, El Alaoui S, Lawry J, et al. (1995) The importance of the GTP binding protein tissue transglutaminase in the regulation of cell cycle progression. FEBS Lett 370: 27-31. doi: 10.1016/0014-5793(95)00782-5
    [15] Olaisen B, Gedde-Dahl TJR, Teisberg P, et al. (1985) A structural locus for coagulation factor XIIIA (F13A) is located distal to the HLA region on chromosome 6p in man. Am J Hum Genet 37: 215-220.
    [16] Yamanishi K, Inazawa J, Liew F-M, et al. (1992) Structure of the gene for human transglutaminase 1. J Biol Chem 267: 17858-17863.
    [17] Gentile V, Davies PJA, Baldini A (1994) The human tissue transglutaminase gene maps on chromosome 20q12 by in situ fluorescence hybridization. Genomics 20: 295-297. doi: 10.1006/geno.1994.1170
    [18] Wang M, Kim IG, Steinert PM, et al. (1994) Assignment of the human transglutaminase 2 (TGM2) and transglutaminase 3 (TGM3) genes to chromosome 20q11.2. Genomics 23: 721-722. doi: 10.1006/geno.1994.1571
    [19] Gentile V, Grant F, Porta R, et al. (1995) Human prostate transglutaminase is localized on chromosome 3p21.33-p22 by in situ fluorescence hybridization. Genomics 27: 219-220.
    [20] Grenard P, Bates MK, Aeschlimann D (2001) Evolution of transglutaminase genes: identification of a transglutaminases gene cluster on human chromosome 15q. Structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z. J Biol Chem 276: 33066-33078.
    [21] Thomas H, Beck K, Adamczyk M, et al. (2013) Transglutaminase 6: a protein associated with central nervous system development and motor function. Amino Acids 44: 161-177. doi: 10.1007/s00726-011-1091-z
    [22] Bailey CDC, Johnson GVW (2004) Developmental regulation of tissue transglutaminase in the mouse forebrain. J Neurochem 91: 1369-1379. doi: 10.1111/j.1471-4159.2004.02825.x
    [23] Kim S-Y, Grant P, Lee JHC (1999) Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminase 1 and 2 in Alzheimer's disease. J Biol Chem 274: 30715-30721.
    [24] lannaccone M, Giuberti G, De Vivo G, et al. (2013) Identification of a FXIIIA variant in human neuroblastoma cell lines. Int J Biochem Mol Biol 4: 102-107.
    [25] Citron BA, Santa Cruz KS, et al. (2001) Intron-exon swapping of transglutaminase mRNA and neuronal tau aggregation in Alzheimer's disease. J Biol Chem 276: 3295-3301. doi: 10.1074/jbc.M004776200
    [26] De Laurenzi V, Melino G (2001) Gene disruption of tissue transglutaminase. Mol Cell Biol 21: 148-155. doi: 10.1128/MCB.21.1.148-155.2001
    [27] Mastroberardino PG, Iannicola C, Nardacci R, et al. (2002) 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ 9: 873-880. doi: 10.1038/sj.cdd.4401093
    [28] Lorand L, Graham RM (2203) Transglutaminases: crosslinking enzymes with pleiotropic functions. Nature Mol Cell Biol 4: 140-156.
    [29] Wolf J, Jäger C, Lachmann I, et al. (2013) Tissue transglutaminase is not a biochemical marker for Alzheimer's disease. Neurobiol Aging 34: 2495-2498. doi: 10.1016/j.neurobiolaging.2013.05.008
    [30] Wilhelmus MMM, Drukarch B (2014) Tissue transglutaminase is a biochemical marker for Alzheimer's disease. Neurobiol Aging 35: e3-e4. doi: 10.1016/j.neurobiolaging.2013.08.022
    [31] Wolf J, Jäger C, Morawski M, et al. (2014) Tissue transglutaminase in Alzheimer's disease - facts and fiction: a reply to “Tissue transglutaminase is a biochemical marker for Alzheimer's disease”. Neurobiol Aging 35: e5-e9. doi: 10.1016/j.neurobiolaging.2013.09.042
    [32] Adams RD, Victor M (1993) Principles of Neurology. McGraw-Hill, Inc. Ed..
    [33] Selkoe DJ, Abraham C, Ihara Y (1982) Alzheimer's disease: insolubility of partially purified paired helical filaments in sodium dodecyl sulfate and urea. Proc Natl Acad Sci U S A 79: 6070-6074. doi: 10.1073/pnas.79.19.6070
    [34] Grierson AJ, Johnson GV, Miller CC (2001) Three different human t isoforms and rat neurofilament light, middle and heavy chain proteins are cellular substrates for transglutaminase. Neurosci Lett 298: 9-12. doi: 10.1016/S0304-3940(00)01714-6
    [35] Singer SM, Zainelli GM, Norlund MA, et al. (2002) Transglutaminase bonds in neurofibrillary tangles and paired helical filament t early in Alzheimer's disease. Neurochem Int 40: 17-30. doi: 10.1016/S0197-0186(01)00061-4
    [36] Halverson RA, Lewis J, Frausto S (2005) Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice. J Neurosci 25: 1226-1233. doi: 10.1523/JNEUROSCI.3263-04.2005
    [37] Jeitner TM, Matson WR, Folk JE, et al. (2008) Increased levels of g-glutamylamines in Huntington disease CSF. J Neurochem 106: 37-44. doi: 10.1111/j.1471-4159.2008.05350.x
    [38] Dudek SM, Johnson GV (1994) Transglutaminase facilitates the formation of polymers of the beta-amyloid peptide. Brain Res 651:129-133. doi: 10.1016/0006-8993(94)90688-2
    [39] Hartley DM, Zhao C, Speier AC, et al. (2008) Transglutaminase induces protofibril-like amyloid b-protein assemblies that are protease-resistant and inhibit long-term potentiation. J Biol Chem 283: 16790-16800. doi: 10.1074/jbc.M802215200
    [40] Citron BA, Suo Z, SantaCruz K, et al. (2002) Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. Neurochem Int 40: 69-78. doi: 10.1016/S0197-0186(01)00062-6
    [41] Junn E, Ronchetti RD, Quezado MM, et al. (2003) Tissue transglutaminase-induced aggregation of a-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 100: 2047-2052. doi: 10.1073/pnas.0438021100
    [42] Zemaitaitis MO, Lee JM, Troncoso JC, et al. (2000) Transglutaminase-induced cross-linking of t proteins in progressive supranuclear palsy. J Neuropathol Exp Neurol 59: 983-989.
    [43] Zemaitaitis MO, Kim SY, Halverson RA, et al. (2003) Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy. J Neuropathol Exp Neurol 62: 173-184.
    [44] Iuchi S, Hoffner G, Verbeke P, et al (2003) Oligomeric and polymeric aggregates formed by proteins containing expanded polyglutamine. Proc Natl Acad Sci U S A 100: 2409-2414. doi: 10.1073/pnas.0437660100
    [45] Gentile V, Sepe C, Calvani M, et al. (1998) Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases. Arch Biochem Biophys 352: 314-321. doi: 10.1006/abbi.1998.0592
    [46] Kahlem P, Green H, Djian P (1998) Transglutaminase action imitates Huntington's disease: selective polymerization of huntingtin containing expanded polyglutamine. Mol Cell 1: 595-601. doi: 10.1016/S1097-2765(00)80059-3
    [47] Karpuj MV, Garren H, Slunt H, et al. (1999) Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc Natl Acad Sci U S A 96: 7388-7393. doi: 10.1073/pnas.96.13.7388
    [48] Segers-Nolten IM, Wilhelmus MM, Veldhuis G (2008) Tissue transglutaminase modulates a-synuclein oligomerization. Protein Sci 17: 1395-1402. doi: 10.1110/ps.036103.108
    [49] Lai T-S, Tucker T, Burke JR, et al. ( 2004) Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats. J Neurochem 88: 1253-1260.
    [50] Konno T, Mori T, Shimizu H, et al. (2005) Paradoxical inhibition of protein aggregation and precipitation by transglutaminase-catalyzed intermolecular cross-linking. J Biol Chem 280: 17520-17525. doi: 10.1074/jbc.M413988200
    [51] The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosome Cell 72: 971-983.
    [52] Banfi S, Chung MY, Kwiatkowski TJ Jr, et al. (1993) Mapping and cloning of the critical region for the spinocerebellar ataxia type 1 gene (SCA1) in a yeast artificial chromosome contig spanning 1.2 Mb. Genomics 18: 627-635. doi: 10.1016/S0888-7543(05)80365-9
    [53] Sanpei K, Takano H, Igarashi S, et al. (1996) Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet 14: 277-284. doi: 10.1038/ng1196-277
    [54] Pujana MA, Volpini V, Estivill X (1998) Large CAG/CTG repeat templates produced by PCR, usefulness for the DIRECT method of cloning genes with CAG/CTG repeat expansions. Nucleic Acids Res 1: 1352-1353.
    [55] Fletcher CF, Lutz CM, O'Sullivan TN, et al. (1996) Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell 87: 607-617. doi: 10.1016/S0092-8674(00)81381-1
    [56] Vincent JB, Neves-Pereira ML, Paterson AD, et al. (2000) An unstable trinucleotide-repeat region on chromosome 13 implicated in spinocerebellar ataxia: a common expansion locus. Am J Hum Genet 66: 819-829. doi: 10.1086/302803
    [57] Holmes SE, O'Hearn E, Margolis RL (2003) Why is SCA12 different from other SCAs? Cytogenet Genome Res 100: 189-197. doi: 10.1159/000072854
    [58] Imbert G, Trottier Y, Beckmann J, et al. (1994) The gene for the TATA binding protein (TBP) that contains a highly polymorphic protein coding CAG repeat maps to 6q27. Genomics 21: 667-668. doi: 10.1006/geno.1994.1335
    [59] La Spada AR, Wilson EM, Lubahn DB, et al. (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352: 77-79. doi: 10.1038/352077a0
    [60] Onodera O, Oyake M, Takano H, et al. (1995) Molecular cloning of a full-length cDNA for dentatorubral-pallidoluysian atrophy and regional expressions of the expanded alleles in the CNS. Am J Hum Genet 57: 1050-1060.
    [61] Cooper AJL, Sheu K-FR, Burke JR, et al. (1999) Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability. J Neurochem 72: 889-899.
    [62] Hadjivassiliou M, Maki M, Sanders DS, et al. (2006) Autoantibody targeting of brain and intestinal transglutaminase in gluten ataxia. Neurology 66: 373-377. doi: 10.1212/01.wnl.0000196480.55601.3a
    [63] Boscolo S, Lorenzon A, Sblattero D, et al. (2010) Anti transglutaminase antibodies cause ataxia in mice. PLoS One 5: e9698. doi: 10.1371/journal.pone.0009698
    [64] Stamnaes J, Dorum S, Fleckenstein B, et al. (2010) Gluten T cell epitope targeting by TG3 and TG6; implications for dermatitis herpetiformis and gluten ataxia. Amino Acids 39: 1183-1191. doi: 10.1007/s00726-010-0554-y
    [65] Wakshlag JJ, Antonyak MA, Boehm JE, et al. (2006) Effects of tissue transglutaminase on beta -amyloid1-42-induced apoptosis. Protein J 25: 83-94. doi: 10.1007/s10930-006-0009-1
    [66] Lee JH, Jeong J, Jeong EM, et al. (2014) Endoplasmic reticulum stress activates transglutaminase 2 leading to protein aggregation. Int J Mol Med 33: 849-855.
    [67] Grosso H, Woo JM, Lee KW, et al. (2014) Transglutaminase 2 exacerbates α-synuclein toxicity in mice and yeast. FASEB J 28: 4280-4291. doi: 10.1096/fj.14-251413
    [68] Basso M, Berlin J, Xia L, et al. (2012) Transglutaminase inhibition protects against oxidative stress-induced neuronal death downstream of pathological ERK activation. J Neurosci 39: 6561-6569.
    [69] Dohil R, Schneider J (2012) Enterically coated cysteamine, cystamine and derivatives thereof. US Patent 20120237599.
    [70] Griffith OW, Larsson A, Meister A (1977) Inhibition of g-glutamylcysteine synthetase by cystamine: an approach to a therapy of 5-oxoprolinuria (pyroglutamic aciduria). Biochem Biophys Res Commun 79: 919-925. doi: 10.1016/0006-291X(77)91198-6
    [71] Igarashi S, Koide R, Shimohata T, et al. (1998) Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat Genet 18: 111-117. doi: 10.1038/ng0298-111
    [72] Karpuj MV, Becher MW, Springer JE, et al. (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 8: 143-149. doi: 10.1038/nm0202-143
    [73] Dedeoglu A, Kubilus JK, Jeitner TM, et al. (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 22: 8942-8950.
    [74] Lesort M, Lee M, Tucholski J, Johnson GVW (2003) Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem 278: 3825-3830.
    [75] Dubinsky R, Gray C (2006) CYTE-I-HD: Phase I Dose Finding and Tolerability Study of Cysteamine (Cystagon) in Huntington's Disease. Movement Disorders 21: 530-533. doi: 10.1002/mds.20756
    [76] Langman CB, Greenbaum LA, Sarwal M, et al. (2012) A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety. Clin J Am Soc Nephrol 7: 1112-20. doi: 10.2215/CJN.12321211
    [77] Besouw M, Masereeuw R, van den Heuvel L, et al. (2013) Cysteamine: an old drug with new potential. Drug Discovery Today 18: 785-792. doi: 10.1016/j.drudis.2013.02.003
    [78] Hadjivassiliou M, Aeschlimann P, Strigun A (2008) Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase. Ann Neurol 64: 332-343. doi: 10.1002/ana.21450
    [79] Krasnikov BF, Kim SY, McConoughey SJ, et al. (2005) Transglutaminase activity is present in highly purified nonsynaptosomal mouse brain and liver mitochondria. Biochemistry 44: 7830-7843. doi: 10.1021/bi0500877
    [80] Bailey CD, Johnson GV (2005) Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms. J Neurochem 92: 83-92. doi: 10.1111/j.1471-4159.2004.02839.x
    [81] Menalled LB, Kudwa AE, Oakeshott S, et al. (2014) Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease. PLoS One 9: e99520. doi: 10.1371/journal.pone.0099520
    [82] Davies JE, Rose C, Sarkar S, et al. (2010) Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy. Sci Transl Med 2: 34-40.
    [83] Lin Y, He H, Luo Y, et al. (2015) Inhibition of transglutaminase exacerbates polyglutamine-induced neurotoxicity by increasing the aggregation of mutant Ataxin-3 in an SCA3 drosophila model. Neurotox Res 27: 259-267. doi: 10.1007/s12640-014-9506-8
    [84] Pietsch M, Wodtke R, Pietzsch J, et al. (2013) Tissue transglutaminase: An emerging target for therapy and imaging. Bioorg Med Chem Lett 23: 6528-6543. doi: 10.1016/j.bmcl.2013.09.060
    [85] Keillor JW, Apperley KYP, Akbar A (2015) Inhibitors of tissue transglutaminase. Trends Pharmacol Sci 36: 32-40. doi: 10.1016/j.tips.2014.10.014
    [86] Bhatt MP, Lim YC, Hwang J, et al. (2013) C-peptide prevents hyperglycemia-induced endothelial apoptosis through inhibition of reactive oxygen species-mediated transglutaminase 2 activation. Diabetes 62: 243-253. doi: 10.2337/db12-0293
  • Reader Comments
  • © 2015 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(6332) PDF downloads(1100) Cited by(0)

Figures and Tables

Figures(5)  /  Tables(2)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog